Medivir participates in the partner and investor conferences Nordic Health Summit in Japan/Korea and BIO KOREA 2026
21 april, 08:30
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of high unmet medical need, announces that the company will participate in two partner and investor conferences in Asia in the coming weeks.
The Nordic Health Summit (NHS) Japan & South Korea is organized by Business Sweden in Tokyo and Seoul on April 23–30 and aims to connect Nordic life science companies with Japanese and Korean companies and investors. In addition to meeting potential partners at the matchmaking session and discussing potential collaborations for the company's two lead drug candidates fostrox and MIV-711, Medivir has also been selected to present to all participants at the meeting in Tokyo.
Medivir's CEO Jens Lindberg will also attend BIO KOREA in Seoul on April 28–30. As one of Asia's premier life science gatherings, the conference attracted more than 700 companies and around 30,000 visitors from 60 countries in 2025.
Jens Lindberg, CEO of Medivir, comments: "Conferences like NHS and BIO KOREA are important platforms for engaging with potential partners. We look forward to presenting our two lead programs — fostrox in advanced liver cancer and MIV-711 in Osteogenesis Imperfecta — both of which address significant unmet medical needs with clear blockbuster potential. I look forward to many productive conversations about potential collaborations."
For more information, please contact:
Jens Lindberg, CEO, Medivir AB
Phone: 08 5468 3100
E-mail: jens.lindberg@medivir.com
About Medivir
About Fostrox
About MIV-711
About Medivir
Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations and partnerships play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com
About fostrox
Fostrox is a liver-targeted inhibitor of DNA replication that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling a chemotherapy (troxacitabine) with a prodrug tail. This design enables fostrox to be administered orally and travel inactive to the liver where activation and release takes place locally in the liver. With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with primary liver cancer and liver metastases from other tumor types. A phase 1b monotherapy study with fostrox has previously been conducted that established clinical proof-of-concept. A phase 1b/2a combination study with fostrox in combination with Lenvima in advanced HCC was completed in November 2024, where data showed encouraging anti-cancer efficacy with a good safety and tolerability profile [1].
About MIV-711
MIV-711 is a potent and selective inhibitor of cathepsin K, the main protease involved in breaking down collagen in bone and cartilage. It has been shown to slow, stop or reverse the progressive degeneration of joints affected by osteoarthritis. By inhibiting cathepsin K and increased/excessive osteoclast activity, MIV-711 has the potential to counteract the excessive bone breakdown seen in patients with Osteogenesis Imperfecta (brittle bone disease). MIV-711 restores the balance between the breakdown of bone with mutated collagen and the formation of new bone with the aim of preventing fractures and bone deformities.
Ämnen i artikeln
Medivir participates in the partner and investor conferences Nordic Health Summit in Japan/Korea and BIO KOREA 2026
21 april, 08:30
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of high unmet medical need, announces that the company will participate in two partner and investor conferences in Asia in the coming weeks.
The Nordic Health Summit (NHS) Japan & South Korea is organized by Business Sweden in Tokyo and Seoul on April 23–30 and aims to connect Nordic life science companies with Japanese and Korean companies and investors. In addition to meeting potential partners at the matchmaking session and discussing potential collaborations for the company's two lead drug candidates fostrox and MIV-711, Medivir has also been selected to present to all participants at the meeting in Tokyo.
Medivir's CEO Jens Lindberg will also attend BIO KOREA in Seoul on April 28–30. As one of Asia's premier life science gatherings, the conference attracted more than 700 companies and around 30,000 visitors from 60 countries in 2025.
Jens Lindberg, CEO of Medivir, comments: "Conferences like NHS and BIO KOREA are important platforms for engaging with potential partners. We look forward to presenting our two lead programs — fostrox in advanced liver cancer and MIV-711 in Osteogenesis Imperfecta — both of which address significant unmet medical needs with clear blockbuster potential. I look forward to many productive conversations about potential collaborations."
For more information, please contact:
Jens Lindberg, CEO, Medivir AB
Phone: 08 5468 3100
E-mail: jens.lindberg@medivir.com
About Medivir
About Fostrox
About MIV-711
About Medivir
Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations and partnerships play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com
About fostrox
Fostrox is a liver-targeted inhibitor of DNA replication that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling a chemotherapy (troxacitabine) with a prodrug tail. This design enables fostrox to be administered orally and travel inactive to the liver where activation and release takes place locally in the liver. With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with primary liver cancer and liver metastases from other tumor types. A phase 1b monotherapy study with fostrox has previously been conducted that established clinical proof-of-concept. A phase 1b/2a combination study with fostrox in combination with Lenvima in advanced HCC was completed in November 2024, where data showed encouraging anti-cancer efficacy with a good safety and tolerability profile [1].
About MIV-711
MIV-711 is a potent and selective inhibitor of cathepsin K, the main protease involved in breaking down collagen in bone and cartilage. It has been shown to slow, stop or reverse the progressive degeneration of joints affected by osteoarthritis. By inhibiting cathepsin K and increased/excessive osteoclast activity, MIV-711 has the potential to counteract the excessive bone breakdown seen in patients with Osteogenesis Imperfecta (brittle bone disease). MIV-711 restores the balance between the breakdown of bone with mutated collagen and the formation of new bone with the aim of preventing fractures and bone deformities.
Ämnen i artikeln
Rapporter
Analys
Rapporter
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
